Clinical trials: Proteinuric Diseases
IgA Nephropathy
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk…
- Trial name
- NCT00922311
- Testing
- Aliskiren
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The University of Hong Kong
Chronic Kidney Disease
Remission Clinic in Proteinuric Chronic Nephropathies
Most chronic kidney diseases have a progressive evolution characterized by the gradual loss of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis and activation of vitamin D.
- Trial name
- NCT02721342
- Testing
- Ramipril, Irbesartan and Atorvastin
- Where
- 13 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Proteinuric Renal Disease, Proteinuric Kidney Disease
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
- Conditions
- Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
- Trial name
- NCT07224776
- Testing
- sparsentan, No sparsentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Gestational Hypertension
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
The investigators do not know which approach to treatment of non-severe high blood pressure in pregnancy is better for women and babies.
- Trial name
- NCT01192412
- Testing
- Intervention is blood pressure management approach, Intervention is blood pressure management approach.
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 987 people
- Sponsor
- University of British Columbia
Primary Membranous Nephropathy
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.
- Trial name
- NCT05800873
- Testing
- EVER001
- Where
- 19 sites in China
- Volunteers
- 31 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Proteinuric Diseases
Phenylbutyrate in Proteinuric Nephropathies
The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.
- Trial name
- PIRATE (NCT02343094)
- Testing
- PBA 7,5g/d, PBA 15g/d
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University
Proteinuria, Diabetic Nephropathy
FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria.
- Conditions
- Proteinuria, Diabetic Nephropathy, Chronic Kidney Disease
- Trial name
- NCT01703234
- Testing
- Ramipril
- Where
- Turkey (Türkiye)
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
IGA Glomerulonephritis
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.
- Trial name
- NCT01115426
- Testing
- Ramipril or losartan
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University Magna Graecia
Chronic Kidney Disease, Unspecified
Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)
The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the…
- Trial name
- PALIFE (NCT01820078)
- Testing
- Experimental arm, Comparator Arm
- Where
- 25 sites in Spain
- Volunteers
- 127 people
- Sponsor
- Fundación Renal Iñigo Alvarez De Toledo
Proteinuric Kidney Disease
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
- Trial name
- NCT06830629
- Testing
- MZE829
- Where
- 79 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Maze Therapeutics
Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
- Trial name
- AMPLITUDE (NCT05312879)
- Testing
- VX-147
- Where
- 314 sites in United States, Belgium and 11 more
- Volunteers
- 522 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Heavy Proteinuria
Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.
- Trial name
- NCT00200694
- Testing
- ramipril 5 mg + valsartan 80 mg/day,, ramipril 10 mg + valsartan 160 mg/day,, ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Nantes University Hospital
Proteinuria
The Effects of Weight Reduction in IgA Nephropathy
The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.
- Trial name
- WeightPro (NCT01773382)
- Testing
- weight reduction
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Renal Insufficiency, Chronic, Proteinuria
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (>65 years old) patients with non-proteinuric nephropathies.
- Trial name
- PROERCAN01 (NCT03195023)
- Testing
- Lisinopril, Amlodipine
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Proteinuria
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.
- Trial name
- NCT01831193
- Testing
- Curcumin
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Chronic Kidney Disease, Proteinuria
Endothelin Receptor Antagonism in Proteinuric Nephropathy
The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria).
- Trial name
- NCT00722215
- Testing
- BQ-123 (selective endothelin A receptor antagonist), 0.9 % saline, Nifedipine
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Edinburgh
Pregnancy Complications, Proteinuria in Pregnancy
Sonoclot to Evaluate Thrombotic Risk in Proteinuric Pregnancy
There is a lack of consensus on whether women with proteinuric kidney disease benefit from prophylactic anticoagulation during pregnancy to reduce the risk of venous thromboembolism.
- Conditions
- Pregnancy Complications, Proteinuria in Pregnancy, Chronic Kidney Diseases, Venous Thromboembolism
- Trial name
- NCT05108389
- Testing
- Viscoelastic haemostasis monitor output
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Nottingham University Hospitals NHS Trust